Plasma-derived medicinal products (PDMPs) are essential medicines required for the treatment of congenital, rare, and acquired diseases. At present, the market dynamics of these products have led to high dependence on a few producing countries, causing shortages, stockouts, and problems related to access in general. To help solve this problem, this document proposes a value model for PDMPs from a public health perspective, and considers the prospects, visions, and challenges to implementation in Colombia, as a case study. These proposals seek to contribute to the development of strategic independence in plasma, while promoting equitable access to PDMPs in the Region of the Americas. They are the result of a series of discussions and semi-structured interviews with national and international stakeholders from different public and private sectors, and with leaders of the National University of Colombia and the International Plasma and Fractionation Association (IPFA). It is hoped that these proposals will serve as an example for other countries in the Region to include this issue in their public policy agenda.